Becton, Dickinson and Co. | BDX - Current Liabilities


Becton, Dickinson and Co. reported $9.54B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Abbott USD 16.15B 1.66B Sep/2026
Agilent USD 2.29B 20M Jun/2026
Align Technology USD 1.91B 4.9M Sep/2026
AngioDynamics USD 71.96M 3.68M Sep/2025
Baxter International USD 3.81B 218M Sep/2026
Becton, Dickinson and Co. USD 9.54B 139M Sep/2026
Bio-Rad Laboratories USD 969.1M 7.8M Sep/2026
Boston Scientific USD 5.98B 446M Sep/2026
Cooper Companies USD 1.87B 61.9M Jun/2026
Danaher USD 9.05B 945M Sep/2026
Dentsply International USD 1.22B 32M Sep/2026
Dexcom USD 2.25B 105.1M Sep/2026
Edwards Lifesciences USD 1.58B 68.8M Sep/2026
Globus Medical USD 507.94M 28.59M Sep/2026
Insulet USD 814.4M 70.2M Sep/2026
Integra LifeSciences USD 329M 1.88M Sep/2026
Intuitive Surgical USD 3.23B 652.4M Sep/2026
J&J USD 55.46B 562M Sep/2026
Medtronic USD 11.8B 141M Jun/2026
Solventum Corp USD 3.58B 88M Sep/2026
Stryker USD 6.5B 184M Sep/2026
Tandem Diabetes Care USD 256.08M 3.07M Sep/2026
Teleflex USD 917.1M 196.72M Sep/2026
Terumo JPY 306.08B 107.19B Sep/2026
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Zimmer Biomet Holdings USD 3.5B 488.9M Sep/2026